NRG-GY007 "A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer" is currently accruing to the Phase II portion.

Patient Population:

Patients with clinically and radiographically suspected and previously untreated FIGO stage III or IV epithelial ovarian, primary peritoneal or fallopian tube cancer, high grade, for whom the plan of management will include neoadjuvant chemotherapy with interval tumor reductive surgery who have undergone biopsies for histologic confirmation. The following histologic epithelial cell types are eligible: high grade serous carcinoma, high grade endometrioid carcinoma, clear cell carcinoma, or a combination of these.

Target Accrual: 162
Status: Open to Accrual
Most Recent Amendment Date: 07/30/2018